Vision
The Platform
Clinical Evidence
Leadership
News & Symposia
Investors
More
March 16, 2026
Field Medical Names Mark Turco, MD as Chief Executive Officer
February 5, 2026
Field Medical Presents Late Breaking Field PULSE Trial Data at AF Symposium 2026
January 12, 2026
Field Medical Inc. to Present at the 44th Annual J.P. Morgan Healthcare Conference
October 10, 2025
Circulation Publishes 6-Month Outcomes from First-in-Human VCAS Trial of FieldForce™ Pulsed Field Ablation System: 82% Freedom from VT/VF Recurrence and 98% Reduction in Burden
First-in-Human VCAS Trial Results with FieldForce™ Ablation System Published in Circulation
October 9, 2025
Field Medical First-in-Human 6-Month Data Selected for Late-Breaking Clinical Trial at VT Symposium 2025
July 1, 2025
Field Medical Closes Oversubscribed $35 Million Series B to Advance Development of FieldForce™ Pulsed Field Ablation Platform
April 23, 2025
Field Medical Announces First-In-Human Data For Focal PFA in Scar-Related VT At-Heart Rhythm 2025
April 21, 2025
Field Medical Closes $40 Million Series A Financing to Redefine Pulsed Field Ablation for Ventricular Tachycardia
December 5, 2024
Field Medical's FieldForce™ Ablation System Earns FDA TAP Pilot Acceptance and Breakthrough Device Designation for the Treatment of Ventricular Tachycardia
media@fieldmedicalinc.com
+1 (980) 412-2298
